港股医药股延续涨势,国内药企签下60亿美元大单,关注恒生创新药ETF、港股通医药ETF等产品

每日经济新闻
21 May

港股医药股延续昨日强势表现,截至10:30,恒生港股通创新药指数上涨3.9%,中证港股通医药卫生综合指数上涨3.2%,均冲击四连涨,两只指数共同成份股中,康方生物上涨7.7%,三生制药上涨7.4%。据悉,辉瑞与三生制药达成协议,就PD-1/VEGF双特异性抗体SSGJ-707达成首付12.5亿美元,总额60.5亿美元的全球开发与商业化协议(除中国内地外),此外辉瑞将于协议生效日认购三生制药价值1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10